Activation of D-2 Dopamine Receptors in CD133+ve Cancer Stem Cells in Non-small Cell Lung Carcinoma Inhibits Proliferation, Clonogenic Ability, and Invasiveness of These Cells

作者：Roy Soumyabrata; Lu Kai; Nayak Mukti Kant; Bhuniya Avishek; Ghosh Tithi; Kundu Suman; Ghosh Sarbari; Baral Rathindranath; Dasgupta Partha Sarathi^*; Basu Sujit^*

来源：JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292(2): 435-445.

DOI：10.1074/jbc.M116.748970

Lung carcinoma is the leading cause of cancer-related death worldwide, and among this cancer, non-small cell lung carcinoma (NSCLC) comprises the majority of cases. Furthermore, recurrence and metastasis of NSCLC correlate well with CD133+ve tumor cells, a small population of tumor cells that have been designated as cancer stem cells (CSC). We have demonstrated for the first time high expression of D-2 dopamine (DA) receptors in CD133+ve adenocarcinoma NSCLC cells. Also, activation of D-2 DA receptors in these cells significantly inhibited their proliferation, clonogenic ability, and invasiveness by suppressing extracellular signal-regulated kinases 1/2 (ERK1/2) and AKT, as well as down-regulation of octamer-binding transcription factor 4 (Oct-4) expression and matrix metalloproteinase-9 (MMP-9) secretion by these cells. These results are of significance as D-2 DA agonists that are already in clinical use for treatment of other diseases may be useful in combination with conventional chemotherapy and radiotherapy for better management of NSCLC patients by targeting both tumor cells and stem cell compartments in the tumor mass.

• 出版日期2017-1-13